Abstracts | 3 proline/alanine-rich kinase (pSPAK) and oxidative stress response kinase-1 (pOSR1), a master regulator of KCC2 and NKCC1 activity. The perisomatic expression of pSPAK/pOSR1 altered correspondingly to that of KCC2 and NKCC1. Finally, we administered diazepam, a GABA A -Receptor agonist, to RS-OVX mice with vehicle, alfaE2 and G1 to confirm the normalization of behavior, KCC2, NKCC1 and GPR30 expression prevents the GABAergic dysfunction. Indeed, diazepam showed anxiolytic and anti-depression-like behavior in alfaE2 and G1 group, but not in vehicle treated group. In summary, alfaE2 mimicked the effect of GPR30 agonist and the effect of alfaE2 were completely diminished by G15, indicating that alfaE2 effect directly or deeply involved in the signal pathway of GPR30. We also found that alfaE2 regulate KCC2/NKCC1 activity via SPAK/OSRI. Thus, we propose alfaE2 as a promising medicine for treatment of neuropsychiatric diseases in postmenopausal women.
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Azapirones for attention deficit hyperactivity disorder: a systematic review Running Head (Short Title): Azapirones for ADHD Yuki Matsui, Fujita Health University, Japan Abstract Introduction: No meta-analysis has evaluated azapirones (serotonin 1A receptor partial agonists) as anxiolytics for attention deficit hyperactivity disorder (ADHD). Methods: Randomized controlled trials (RCTs) and single-arm trials published before 2015/10/27 were retrieved from major healthcare databases and clinical trial registries. Relative risk and 95% confidence intervals were calculated. Results: Five RCTs (n = 429) and two single-arm studies (n = 62) were identified. Three RCTs compared buspirone versus methylphenidate in children/adolescents, one buspirone patches versus placebo patches in children/adolescents, and one atomoxetine plus buspirone versus atomoxetine versus placebo in adults. The single-arm studies were buspirone trails in children/ adolescents. All-cause discontinuation rates and adverse events did not differ between pooled buspirone and methylphenidate groups. No other meta-analyses of buspirone efficacy and safety versus comparators were conducted due to insufficient data. Two RCTs found no significant differences in parent and teacher ADHD-Rating Scale total scores between buspirone and methylphenidate, while one reported that methylphenidate improved parent and teacher ADHD-RS total scores versus buspirone. Discussion: It has remained unclear whether buspirone use has benefit for ADHD patients and therefore further evidence is needed for better clinical use of buspirone in patients with ADHD.
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Increased white matter connectivity in traumatized children with attention deficit hyperactivity disorder 
